Pharmaceutical Marketing: A Contrast of Different Markets
DOI:
https://doi.org/10.59890/ijebma.v1i2.386Keywords:
Drug Consumption, Drug Market, Fitness Chance, Prescription Drugs Studies, Public Rules IntroductionAbstract
Pharmaceutical Marketing is a versatile field that varies considerably across various markets, compelled by diverse supervisory atmospheres, service behaviors, and healthcare structures. This item provides a brief overview and corresponding blueprints for drug marketing in developed and emerging markets. In developed markets like the United States and Western Europe, drug shopping is characterized by intense competition, tight management, and a strong emphasis on direct-to-service billing. Pharmaceutical companies laboriously test drugs, often developing costly ones. Consequently, shopping efforts devote effort to something that establishes brand knowledge and differentiates brands. Direct-to-service announcements, through television, print, and mathematical radio, play a pivotal function in these markets, often accompanying customers in distinguishing drugs by name and following physician prescribing patterns. In contrast, emerging markets such as India and Brazil, present a variety of landscapes Here, the foundation and approach to cures are challenges, and pricing pressures are more important. Pharmaceutical parties in these domains often plan out general translations of drugs due to economic constraints. Marketing plans in emerging markets frequently include a more meaningful emphasis on affordability, approach ability, and alliances with local healthcare providers. Moreover, word-of-mouth shopping and society's health laborers play a critical role in influencing patient selections. Pharmaceutical shopping in two developed and emerging markets nevertheless faces growing scrutiny concerning moral practices, transparency, and the balance between profits and community health. The regulatory crowd everywhere is tightening their belts to guarantee that shopping efforts do not compromise patient security or information for purchasers
References
Lid stone, J. (n.d.). Advertising Planning for the Pharmaceutical Industry. Retrieved November 16, 2019, from https://www.pharmaceutical- advertising.net/pharmaceutical-marketing/advertising-planning-for-the- pharmaceutical-industry/
(1) Bick, A., & Manchanda, P. (2016). Pharmaceutical Advertising: Issues and Challenges. International Journal of Business and Social Science, 7(1), 95- 101."Patient Information Leaflet." NHS, www.nhs.uk/conditions/patient- information-leaflets/.
Klein, G. (2019). Marketing authorization Holder. Retrieved from https://www.ema.europa.eu/en/human-regulatory/post- authorisation/marketing-authorisation-holder
AAA. "Brand." American Advertising and Marketing Association, www.americanmarketingassociation.org/brand/.
J.J.Kapferer, Strategic Brand Management, Kogan Page, London, 2008, p. 79
S. Keller, Strategic Brand Management, Prentice Hall, Upper Saddle River, NJ,2008,p.48
A.V. Manohar, Strategic Brand Management, Oxford University Press, New Delhi, 2014, p. 131
A.M. McGann, Strategic Brand Management, Oxford University Press, Oxford, 2016, p. 54
Ducoffe, R. (1996).The Value of a Brand Name. Harvard Business Review, 74(4), pp. 33-44
Bertrand, Joseph. “From Clinical Trials to Branding: How AstraZeneca Has Changed the Way Drugs Are Marketed.” The Journal of Business Strategy, vol. 39, no. 4, 2018, pp. 44–50.
Hinds, D. (2013). The Role Of Branding In Pharmaceuticals. The Pharmaceutical Journal, 290(7736), 74-76. doi:10.1211/PJ.2013.20221121
Lorence, D. (2005). The importance of pharmaceutical branding. Pharmaceutical Executive, 25(8), 22-25.
US Food and Drug Administration. "What We Do." FDA, U.S. Food and Drug Administration, www.fda.gov/about-fda/what-we-do.
US Food and Drug Administration. "Mis branding of Drugs - Section 502(n)." FDA, U.S. Food and Drug Administration, www.fda.gov/regulatory- information/search-FDA-guidance documents/misbranding-drugs- section-502n.
U.S. Food and Drug Administration. "FDA Overview of the Drug Development Process." U.S. Food and Drug Administration, U.S. Department of Health and Human Services, 8 June 2017, www.fda.gov/drugs/DevelopmentApprovalProcess/default.htm.
"Overview of FDA Authority to Regulate Drug Promotion." DDMAC, Division of Drug Marketing, Advertising, and Communications, fda.gov/drugs/drug-information-consumers/overview-FDA-authority- regulate-drug-promotion.
"FDA Authority Over Promotion and Advertising of Pharmaceuticals." FDA, U.S. Food and Drug Administration, 30 Apr. 2018, www.fda.gov/drugs/resources-information-approved-drugs/fda- authority-over-promotion-and-advertising-pharmaceuticals.
U.S. Food and Drug Administration. (2019). Division of Drug Marketing, Advertising, and Communications (DDMAC). Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research- cder/division-drug-marketing-advertising-and-communications-ddmac
Tuttle, K. (n.d.). What is DDMAC and How Does it Impact Pharmaceutical Marketing? Retrieved April 28, 2019, from https://www.pm360online.com/what-is-ddmac-and-how-does-it-impact- pharmaceutical-marketing/
Kawai, M., & Sugimoto, Y. (2013). Regulatory framework and current status of pharmaceuticals and medical devices in Japan. International journal of clinical pharmacy, 35(6), 1130-1135.
Pollard, M. (2008). Support for Continuing Medical Education. American Journal of Pharmaceutical Education, 72(3). Retrieved from https://search.proquest.com/docview/217408046?accountid=14512
Hall, J. (2018). Ethical Marketing of Pharmaceutical Products. The Pharmaceutical Journal, 300(7898), 35-38
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rehan Haider

This work is licensed under a Creative Commons Attribution 4.0 International License.



